Dose titration to reduce dipyridamole-related headache

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Low-dose aspirin and modified-release dipyridamole (ASA+MR-DP) combination therapy offers superior stroke prevention compared to aspirin alone.
• Headaches are a notable side effect associated with dipyridamole-containing agents.
• The need for improved tolerance in patients undergoing stroke prevention therapy is critical.

Purpose of the Study:

• To evaluate the tolerability of different dosing regimens of ASA+MR-DP in patients with a history of ischemic cerebrovascular disease.
• To compare the incidence and severity of headaches between reduced-dose and regular-dose ASA+MR-DP treatments.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 146 patients.
• Three groups were studied: placebo, reduced dose ASA+MR-DP, and regular dose ASA+MR-DP.
• Headache incidence and intensity were assessed using a diary card and graded according to standard toxicity criteria.

Main Results:

• The regular dose ASA+MR-DP group showed a significantly higher incidence of headaches (38.8%) compared to other groups (p < 0.05).
• Mean cumulative headache scores were significantly higher in the regular dose group during the initial treatment phase (days 5-14).
• Headache was the primary reason for dropout, particularly in the regular dose group, although this difference was not statistically significant.

Conclusions:

• An initial reduced-dose regimen of ASA+MR-DP appears to be better tolerated, leading to fewer headaches than regular dosing.
• This approach may be particularly beneficial for patients prone to headaches associated with phosphodiesterase inhibitor use.
• Optimizing the initial dosing strategy can improve patient adherence and treatment outcomes in stroke prevention.